RT Book, Section
A1 Fravel, Michelle A.
A1 Ernst, Michael E.
A2 DiPiro, Joseph T.
A2 Talbert, Robert L.
A2 Yee, Gary C.
A2 Matzke, Gary R.
A2 Wells, Barbara G.
A2 Posey, L. Michael
SR Print(0)
ID 1164577366
T1 Gout and Hyperuricemia
T2 Pharmacotherapy: A Pathophysiologic Approach, 10e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781259587481
LK accesspharmacy.mhmedical.com/content.aspx?aid=1164577366
RD 2024/04/24
AB Content  UpdateAugust  7,  2019FDA  Warns  of  Increased  Risk  of  Death  with  Febuxostat  in  Patients  with  Gout  and  Cardiovascular  Disease:  In  February  2019,  the  U.S.  Food  and  Drug  Administration  issued  a  new  boxed  warning  and  Medication  Guide  for  febuxostat  (Uloric),  a  xanthine  oxidase  inhibitor  used  to  lower  serum  uric  acid  concentrations  in  patients  with  gout.  In  a  randomized  controlled  study  (the  CARES  trial),  febuxostat  was  associated  with  an  increased  risk  of  cardiovascular  death  and  death  from  any  cause  when  compared  with  allopurinol.  Based  on  the  labeling  change,  febuxostat  should  only  be  prescribed  for  patients  who  have  had  an  inadequate  response,  intolerance,  or  contraindications  to  allopurinol.  Patients  should  be  informed  of  the  potential  for  adverse  cardiovascular  events  and  advised  to  notify  their  healthcare  provider  if  cardiovascular  symptoms  occur.